Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL31140087 | 0.87 | GABRA1 (0.46) | GABRA1GABRB2POLBKDM4EMAPT | |
| SCHEMBL664647 | 0.77 | HDAC8 (0.42) | GABRA1GABRB2GAAMAPTRXRA | |
| SCHEMBL93161 | 0.76 | GABRA1 (0.69) | GABRA1GABRB2POLBKDM4EGAA | |
| SCHEMBL663624 | 0.74 | TSHR (0.48) | MAPTALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL14763886 | 0.74 | GABRA1 (0.46) | GABRA1GABRB2POLBKDM4EGAA | |
| SCHEMBL432591 | 0.74 | CES2 (0.41) | MAPTRXRARXRBRXRGALDH1A1 | |
| SCHEMBL3162653 | 0.74 | GABRA1 (0.46) | GABRA1GABRB2POLBKDM4EGAA | |
| SCHEMBL10394690 | 0.73 | GABRA1 (0.65) | GABRA1GABRB2POLBKDM4EGAA | |
| SCHEMBL10415675 | 0.73 | GABRA1 (0.65) | GABRA1GABRB2POLBKDM4EGAA | |
| Bromide SCHEMBL2959626 | 0.72 | TSHR (0.46) | MAPTALDH1A1HPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115448918-B | Phenanthroline ligand and application thereof in copper-catalyzed aryl halide coupling reaction | 江西德璟生物科技有限公司 | 2023-07-25 | — | — | CN | claimed |
| US-12520720-B2 | Heterocyclic compound and organic light-emitting device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2026-01-06 | — | — | US | disclosed |
| EP-3617202-B1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG ELECTRONICS CO LTD (KR) | 2025-11-05 | — | — | EP | disclosed |
| CN-119462781-A | Ligand, catalyst, chiral alcohol and synthesis method thereof | 深圳格林凯特医药技术有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-115448918-B | Phenanthroline ligand and application thereof in copper-catalyzed aryl halide coupling reaction | 江西德璟生物科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11578148-B2 | Metal complex comprising amidine and thiophene fused cyclopentadienyl ligands | ARLANXEO NETHERLANDS B.V. | 2023-02-14 | — | — | US | disclosed |
| CN-110177798-B | Catalyst and process for preparing same | 博里利斯股份公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114644662-A | Chiral phosphine nitrogen tridentate ligand based on ferrocene structure and application thereof | 广东工业大学 | 2022-06-21 | — | — | CN | disclosed |
| US-11352376-B2 | Catalysts | BOREALIS AG (AT) | 2022-06-07 | — | — | US | disclosed |
| EP-3732183-B1 | METAL COMPLEX COMPRISING AMIDINE AND THIOPHENE FUSED CYCLOPENTADIENYL LIGANDS | Arlanxeo Netherlands Bv (NL) | 2021-10-20 | — | — | EP | disclosed |
| US-6380120-B1 | AS POLYMERIZATION CATALYST | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-04-30 | — | — | US | disclosed |
| US-6376627-B1 | COORDINATION CATALYSTS | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-04-23 | — | — | US | disclosed |
| US-6376410-B1 | COORDINATION POLYMERIZATION CATALYST ON SUPPORT | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-04-23 | — | — | US | disclosed |
| US-6376407-B1 | COORDINATION POLYMERIZATION CATALYST | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-04-23 | — | — | US | disclosed |
| US-6376408-B1 | COORDINATION POLYMERIZATION CATALYST ON SUPPORT | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-04-23 | — | — | US | disclosed |
| US-6376412-B1 | COORDINATION POLYMERIZATION CATALYST ON SUPPORT | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-04-23 | — | — | US | disclosed |
| US-6376409-B1 | COORDINATION POLYMERIZATION CATALYST ON SUPPORT | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-04-23 | — | — | US | disclosed |
| US-6376413-B1 | COORDINATION POLYMERIZATION CATALYST ON SUPPORT | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-04-23 | — | — | US | disclosed |
| US-6376411-B1 | COORDINATION POLYMERIZATION CATALYST ON SUPPORT | EXXONMOBIL CHEMICAL PATENTS INC. | 2002-04-23 | — | — | US | disclosed |
| WO-2002002575-A1 | METALLOCENES WITH A BRIDGED 4-PHENYL-INDENYL-LIGAND FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352376-B2 | Catalysts | SIGMAR1, H1-2, SFN | GABRA1 3084/4885GABRB2 3318/4885POLB 2707/4885 |
| US-11578148-B2 | Metal complex comprising amidine and thiophene fused cyclopentadienyl ligands | AP3M1, AP2M1, AP1M1 | GABRA1 4080/4885GABRB2 4720/4885POLB 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.